Variant Bio partners with Boehringer Ingelheim for Research on Kidney Disease
The multi-year collaboration with Boehringer Ingelheim will leverage Variant Bio’s AI-powered Inference platform to identify novel kidney disease drug targets, with financial terms including upfront, licence and milestone payments that could exceed USD 120 million.
Research Collaboration | 08/01/2026 | By News Bureau
Ipsen and Skyhawk Therapeutics to Work on RNA Targeting Research in Rare Neurological Diseases
Ipsen has signed an exclusive worldwide collaboration with Skyhawk Therapeutics to discover and develop novel small molecules that modulate RNA for rare neurological diseases.
Research Collaboration | 22/04/2024 | By Aishwarya | 345
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy